14 / 21
Preventive Medicine 2018
Journal of Preventive Medicine
ISSN: 2572-5483
Page 40
July 16-17, 2018
London, UK
9
th
Edition of International Conference on
Preventive Medicine
& Public Health
S
ubclinical multiple sclerosis (S-MS) can be usually defined as the
discovery of characteristic lesions at magnetic resonance (MR) or
at autopsy, in the absence of clinical evidence consistent with MS. The
methodological bricks of subclinical diagnostic and predictive protocols
should include basic algorithms to differ essentially from those employed
in canonical clinical practice, i.e., (i) to confirm a diagnosis of subclinical
stage of the disease course and (ii) to select a mode for preventive
treatment to quench the autoimmune inflammation. In this sense, among
the best-validated proteome-related translational biomarkers, antibody-
proteases were proven to be the best known ones. Abs against myelin
basic protein/MBP endowing with proteolytic activity (Ab-proteases
with functionality) is of great value to monitor demyelination to illustrate
the evolution of MS. The activity of the MBP-targeted Ab-proteases
discovered in MS patients markedly differs between: (i) MS patients and
healthy controls; (ii) different clinical MS courses; (iii) EDSS scales of
demyelination to correlate with the disability of MS patients to predict
the transformation prior to changes of the clinical course. The activity
of Ab-proteases was first registered at the subclinical stages 1-2 years
prior to the clinical illness. About 24% of the direct MS-related relatives
(probands)wereseropositiveforlow-activeAb-proteasesfromwhich38%
of the seropositive relatives established were beingmonitored for 2 years
whilst demonstrating a stable growth of the Ab-associated proteolytic
activity. Three patients were initially evaluated because of accidental
MRI findings suggestive of MS that fulfilled the Barkhof criteria. At the
moment of MR examination, patients were asymptomatic. The objective
examinations as well as the clinical history were negative. After having
those patients tested for Ab-proteases, all three have demonstrated
elevated levels of the specific activity to target MBP. We have been
monitoring along with the patients mentioned all direct members (13
healthy persons) of their families for 2 years and found that 3 relatives
tested had elevated levels of the specific activity which was having a
trend to grow whilst correlating with clinical symptoms of MS including
the chronic fatigue, muscle weakness, dizziness, etc. All family members
were studied with MRI, evoked potentials, and human leukocyte antigen
(HLA) typing. The activity of Ab-proteases and its dynamics tested would
confirm a high subclinical and predictive (translational) value of the tools
as applicable for personalized monitoring protocols. Further studies on
targeted Ab-mediated proteolysis may provide a translational tool for
predicting demyelination and thus the disability of the MS patients in a
variety of clinical and subclinical cases.
Biography
Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty
medical doctors. In 1980, graduated from Astrakhan State Medical University and
was awarded withMD. In 1985, Suchkov maintained his PhD as a PhD student of the
I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology. At
present, Dr Sergey Suchkov, MD, PhD, is: Professor, Director, Center for Personalized
Medicine, I.M.Sechenov First Moscow State Medical University and Dept of Clinical
Immunology, A.I.Evdokimov Moscow State Medical and Dental University; Professor,
Chair, Dept for Translational Medicine, Moscow Engineering Physical Institute (ME-
PhI), Russia Dr Suchkov is amember of the: American Heart Association (AHA), USA;
European Association for Medical Education (AMEE), Dundee, UK; ● EPMA (European
Association for Predictive, Preventive and Personalized Medicine), Brussels, EU;.
ssuchkov57@gmail.comFunctionality armed antibodies as new translational tools tomonitor
progression of chronic disorders at clinical and subclinical stages
Sergey Suchkov
1, 2
, Noel Rose
3, 4
, Aleks Gabibov
5
, Harry Schroede
6
, Abner Not-
kins
2
and
Trevor Marshall
7
1
Sechenov University, A I Evdokimov Moscow State Medical & Dental University and
Moscow Engineering Physical Institute (MEPhI), Moscow, Russia
2
National Institutes of Health, Bethesda, USA
3
Center for Autoimmune Disease Research - Johns Hopkins Medicine, USA
4
Harvard Medical School, USA
5
Institute for Bioorganic Chemistry - Russian Academy of Sciences, Russia
6
University of Alabama at Birmingham, USA
7
Autoimmunity Research Foundation, California, USA
Sergey Suchkov et al., J Prev Med 2018, Volume 3
DOI: 10.21767/2572-5483-C1-002